Skip to main content
. 2018 Sep 21;9(74):33947–33960. doi: 10.18632/oncotarget.26103

Figure 4. c-Src kinase activity in HBV-replicating hepatoma cells.

Figure 4

(a) Total protein levels of c-Src kinase and its tyrosine 416 phosphorylated activated form (Tyr416) as well as HBV core protein were subjected to Western blot analysis in parental (−) compared to HBV-replicating (H1.3 + H1.3x−) HepG2 cells. (b) Total protein levels of the c-Src tyrosine 416 phosphorylated activated form (Tyr416) were subjected to Western blot analysis in HBV-replicating HepG2H1.3 cells either treated with the reverse transcriptase inhibitor Entecavir (+) or not (−).